Skip to content

This website is intended for UK healthcare professionals only

This is a promotional website developed by AstraZeneca

The prescribing information can be found at the bottom of the page


Osimertinib Clinical Trials

Explore the pages below to learn more about the key trials relating to TAGRISSO® (osimertinib)

To request the ADAURA or FLAURA publications, please click here

FLAURA graphic

Flaura Clinical Trial

The FLAURA trial was a double-blind, phase 3 trial involving patients with previously untreated advanced NSCLC with EGFR mutations that compared the efficacy and safety profiles of osimertinib with that of two other EGFR-TKIs, gefitinib or erlotinib.

lungs graphic
New data available

Adaura Clinical Trial

The ADAURA trial was a double-blind, phase 3 trial which randomly assigned patients with completely resected EGFRm NSCLC to receive either Tagrisso (osimertinib) or placebo for 3 years